Stereotactic ablative radiotherapy for stage I lung cancer: a retrospective single institution report in Western Australia

Abstract

Objectives: Stereotactic ablative radiotherapy (SABR) is now standard management of stage I non-small cell lung cancer in patients who are not medically operable. The purpose of this study was to assess clinical outcomes in our single institution to review comparability with worldwide outcomes. Methods: The institutional database was screened for all patients with Stage I NSCLC treated in between September 2010 to November 2018 with SABR. Local control was defined on PET/CT or CT imaging and survival status retrieved from electronic medical records. Overall survival and local control were calculated using Kaplan-Meier method. Results: 93 patients were treated with SBRT for stage I NSCLC. Median follow up time was 30 months (range 1-99 months). Overall survival was 67% and local control was 91% at 3 years respectively. Toxicity included grade 1-2 pneumonitis (16.5%), chest wall pain (3.3%) and rib fracture (2.1%) Conclusion: In our local institution SABR for Stage I NSCLC is a safe and effective form of management of medically inoperable patients.